NCI Debuts New Program for Cancer Advocates

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 4
Volume 10
Issue 4

BETHESDA, Md-The National Cancer Institute has opened its arms wider to the advocacy community with a new program called Consumer Advocates in Research and Related Activities, or CARRA. NCI plans to recruit 150 consumer advocates under the CARRA program who will serve 3-year terms. The advocates are to represent survivors’ concerns, provide their ideas and viewpoints directly to the NCI staff, and serve as links between the advocacy communities and the Institute.

BETHESDA, Md—The National Cancer Institute has opened its arms wider to the advocacy community with a new program called Consumer Advocates in Research and Related Activities, or CARRA. NCI plans to recruit 150 consumer advocates under the CARRA program who will serve 3-year terms. The advocates are to represent survivors’ concerns, provide their ideas and viewpoints directly to the NCI staff, and serve as links between the advocacy communities and the Institute.

CARRA advocates must be cancer survivors, or a family member or life partner of a person with cancer, or have been involved for 3 years or more in cancer activities. CARRA applications are available at http://liaison.cancer.gov/CARRA.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content